UPDATE, 3:30 p.m. Nov. 2: Ameridose, the Westborough facility that shares owners with the Framingham company connected to a national meningitis outbreak, will be closed until at least Nov. 19.

The temporary closure of Ameridose LLC, by mutual agreement with state regulators, was extended to give investigators more time to inspect the facility, the Boston Globe reported.

ORIGINAL STORY:

The Boston Globe reports that Ameridose voluntarily has recalled all of its drugs following an ongoing FDA inspection of the Westborough facility.

In a press release today, Ameridose officials said the recall "represents an expansion of our cooperation with the U.S. Food and Drug Administration and the Massachusetts Board of Registration in Pharmacy."

"During the course of its on-going inspection of our facility, FDA has notified Ameridose that it will be seeking improvements in Ameridose's sterility testing process," the press release states.

"Ameridose and FDA agree that the use of injectible products that are not sterile can represent a serious hazard to health and could lead to life-threatening injuries and/or death.

"Ameridose has not received any adverse reports related to the products subject to this recall and neither Ameridose nor the FDA has identified impurities in any Ameridose products.  Nevertheless, out of an abundance of caution, we are undertaking this recall to assure customers that when Ameridose products are shipped, they are fully in conformance with all of the FDA's recommendations."

Amerdose shares owners with the New England Compounding Center in Framingham, which has been linked to the national deadly meningitis outbreak.

Ameridose recently agreed to close until Nov. 5, so it can be inspected.

Check out Patch's coverage of the meningitis outbreak here.